Synthetic lethality-mediated precision oncology via the tumor transcriptome

45Citations
Citations of this article
297Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Precision oncology has made significant advances, mainly by targeting actionable mutations in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun to explore the utility of tumor transcriptome to guide patient treatment. Here, we introduce SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a precision oncology framework harnessing genetic interactions to predict patient response to cancer therapy from the tumor transcriptome. SELECT is tested on a broad collection of 35 published targeted and immunotherapy clinical trials from 10 different cancer types. It is predictive of patients’ response in 80% of these clinical trials and in the recent multi-arm WINTHER trial. The predictive signatures and the code are made publicly available for academic use, laying a basis for future prospective clinical studies.

Cite

CITATION STYLE

APA

Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., … Ruppin, E. (2021). Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell, 184(9), 2487-2502.e13. https://doi.org/10.1016/j.cell.2021.03.030

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free